Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVES: Health-related quality of life (HRQOL) is an important outcome within value-based care for patients with neurologic conditions. The American Academy of Neurology recommends the use of Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health as a patient-reported outcome performance measure to assess stability or improvement over 1 year. However, interpretation of this measure requires an understanding of HRQOL across neurologic populations. Our study leveraged real-world data collected through the electronic health record to characterize differences in HRQOL across common neurologic conditions. METHODS: This is a cross-sectional study of adult patients with 1 of 10 conditions (amyotrophic lateral sclerosis [ALS], back pain, brain tumor, dementia, major depression, epilepsy, migraine, multiple sclerosis, Parkinson disease, and stroke) who completed patient-reported outcomes as standard care between October 2015 and March 2023 at a large Neurologic Institute. Patients completed PROMIS-GH, from which physical and mental summary scores (Global Mental Health [GMH], Global Physical Health [GPH]) were calculated, PHQ-9 depression screen, and condition-specific measures. EQ-5D utility index was estimated from PROMIS-GH. These were summarized across conditions after adjustment for demographics, clinical characteristics, and self-reported condition-specific severity. RESULTS: There were 133,636 patients included in this analysis (mean age 51.5 [SD ± 18] years, 64% female, 81% White race). Overall adjusted average scores for GPH, GMH, PHQ-9, and EQ-5D were 42.7 ± 5.0, 43.6 ± 5.0, 7.9 ± 3.7, and 0.68 ± 0.11, respectively. Scores were significantly different across condition, with GPH ranging from 39.6 ± 5.5 for back pain to 45.9 ± 3.9 for brain tumor. Patients with brain tumor, back pain, stroke, ALS, and multiple sclerosis had more favorable GMH and PHQ-9 scores, while patients with depression, epilepsy, and dementia had the most affected GMH and PHQ-9 scores. Patients with back pain and headache had the lowest EQ-5D scores (0.63 ± 0.13 and 0.67 ± 0.09), while those with brain tumor had the highest (0.77 ± 0.08). DISCUSSION: This study provides condition-specific and severity-specific benchmarks for PROMIS-GH and related HRQOL measures that can support interpretation of patient-reported outcomes across neurologic populations. These data inform clinical care, quality measurement, research, and the implementation of the AAN-recommended performance measure.
No takes yet. Share an insight, caveat, or question.
Lapin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: